Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial.

Autor: Szymura SJ; Stephenson Lymphoma Center, Beckman Research Institute and Hematologic Malignancies Research Institute, City of Hope, Duarte, CA, USA., Wang L; Department of Computational and Quantitative Medicine, Beckman Research Institute and Hematologic Malignancies Research Institute, City of Hope, Duarte, CA, USA., Zhang T; Stephenson Lymphoma Center, Beckman Research Institute and Hematologic Malignancies Research Institute, City of Hope, Duarte, CA, USA., Cha SC; Stephenson Lymphoma Center, Beckman Research Institute and Hematologic Malignancies Research Institute, City of Hope, Duarte, CA, USA., Song J; Division of Hematopathology, Department of Pathology, City of Hope, Duarte, CA, USA., Dong Z; Stephenson Lymphoma Center, Beckman Research Institute and Hematologic Malignancies Research Institute, City of Hope, Duarte, CA, USA., Anderson A; Stephenson Lymphoma Center, Beckman Research Institute and Hematologic Malignancies Research Institute, City of Hope, Duarte, CA, USA., Oh E; Stephenson Lymphoma Center, Beckman Research Institute and Hematologic Malignancies Research Institute, City of Hope, Duarte, CA, USA., Lee V; Stephenson Lymphoma Center, Beckman Research Institute and Hematologic Malignancies Research Institute, City of Hope, Duarte, CA, USA., Wang Z; Stephenson Lymphoma Center, Beckman Research Institute and Hematologic Malignancies Research Institute, City of Hope, Duarte, CA, USA., Parshottam S; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Rao S; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Olsem JB; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Crumpton BN; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Lee HC; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Manasanch EE; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Neelapu S; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Kwak LW; Stephenson Lymphoma Center, Beckman Research Institute and Hematologic Malignancies Research Institute, City of Hope, Duarte, CA, USA. lkwak@coh.org., Thomas SK; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

Publikováno v: Nature communications [Nat Commun] 2024 Aug 11; Vol. 15 (1), pp. 6874. Date of Electronic Publication: 2024 Aug 11.

Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain.

Autor: Mikkilineni L; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Natrakul DA; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Lam N; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Manasanch EE; University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mann J; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Weissler KA; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Wong N; Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research in the CCR Collaborative Bioinformatics Resource, National Cancer Institute, Bethesda, MD, USA., Brudno JN; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Goff SL; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yang JC; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Ganaden M; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Patel R; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zheng Z; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Gartner JJ; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Martin KR; Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA., Wang HW; Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Yuan CM; Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Lowe T; Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Maric I; Hematology Service, Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, MD, USA., Shao L; Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA., Jin P; Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA., Stroncek DF; Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA., Highfill SL; Center for Cellular Engineering, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA., Rosenberg SA; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Kochenderfer JN; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: kochendj@mail.nih.gov.

Publikováno v: Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2024 Feb 07; Vol. 32 (2), pp. 503-526. Date of Electronic Publication: 2023 Dec 28.

Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma.

Autor: Setayesh SM; Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, 90089, USA., Ndacayisaba LJ; Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, 90089, USA., Rappard KE; Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, 90089, USA., Hennes V; Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, 90089, USA., Rueda LYM; Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Tang G; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Lin P; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Orlowski RZ; Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Symer DE; Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Manasanch EE; Department of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Shishido SN; Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, 90089, USA. sshishid@usc.edu., Kuhn P; Convergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, 90089, USA. pkuhn@usc.edu.; Catherine & Joseph Aresty Department of Urology, Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA. pkuhn@usc.edu.; Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA. pkuhn@usc.edu.; Department of Biomedical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA, 90089, USA. pkuhn@usc.edu.; Department of Aerospace and Mechanical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA, 90089, USA. pkuhn@usc.edu.; Department of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, CA, 90089, USA. pkuhn@usc.edu.

Publikováno v: NPJ precision oncology [NPJ Precis Oncol] 2023 Sep 18; Vol. 7 (1), pp. 95. Date of Electronic Publication: 2023 Sep 18.

Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease.

Autor: Dang M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang R; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee HC; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel KK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Becnel MR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Han G; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thomas SK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hao D; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chu Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Weber DM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lin P; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lutter-Berka Z; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Berrios Nolasco DA; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huang M; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bansal H; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Song X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Futreal A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Moreno Rueda LY; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Symer DE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Green MR; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rojas Hernandez CM; Department of Internal Medicine, Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kroll M; Department of Internal Medicine, Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Afshar-Khargan V; Department of Internal Medicine, Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ndacayisaba LJ; University of Southern California, Los Angeles, CA, USA., Kuhn P; University of Southern California, Los Angeles, CA, USA., Neelapu SS; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA. Electronic address: lwang22@mdanderson.org., Manasanch EE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: eemanasanch@mdanderson.org.

Publikováno v: Cancer cell [Cancer Cell] 2023 Jun 12; Vol. 41 (6), pp. 1032-1047.e4.

Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma: a prospective series.

Autor: Chiu CY; Department of Infectious Diseases, The University of Texas Health Science Center at Houston, Houston, TX, USA.; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mustafayev K; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lee HC; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Manasanch EE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yepez Guevara E; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Torres HA; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2023 Apr; Vol. 64 (4), pp. 900-903. Date of Electronic Publication: 2023 Mar 08.